Product
HRS-8080
Aliases
HRS-8080; Dalpiciclib Isethionate Tablets, HRS-8080; SHR-A1811, HRS-8080; SHR-A2009
2 clinical trials
1 indication
Indication
Breast CancerClinical trial
A Multicenter, Open Phase Ib/II Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of HRS-8080 in Combination With Dalpiciclib Isethionate Tablets in Patients With ER-positive, HER2-negative Unresectable or Metastatic Breast CancerStatus: Recruiting, Estimated PCD: 2025-10-31
Clinical trial
A Multi-center, Open-label Phase Ib/II Clinical Study on the Safety, Tolerability, Pharmacokinetics and Efficacy of HRS-8080 or SHR-A2009 Combined With Anti-tumor Therapy in Patients With Unresectable or Metastatic Breast CancerStatus: Not yet recruiting, Estimated PCD: 2026-10-31